Seminars in Oncology
Volume 32, Issue 2 , Pages 145-155 , April 2005

Palliative chemotherapy: Historical perspective, applications, and controversies

  • Ilene Browner

      Affiliations

    • Divisions of Medical Oncology and Geriatric Medicine and Gerontology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD, USA
    • ,
  • Michael A. Carducci

      Affiliations

    • Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD, USA
    • Corresponding Author InformationAddress reprint requests to Michael A. Carducci, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CRB IM89, 1650 Orleans St, Baltimore, MD 21231-2410.

References 

  1. Jemal A , Murray T , Ward E , et al.   Cancer statistics, 2005 . CA Cancer J Clin . 2005;55:10–30
  2. Institute of Medicine: Improving palliative care for cancer: Summary and recommendation . 2003; http://books.nap.edu/catalog/10147.html
  3. Carducci M, Zobera JR, Meyer FJ, et al: Simultaneous care: Linking palliative care to clinical trials. http://jhmcis.jhmi.edu/oncres/Protocols/J0274.pdf
  4. Byock I . Completing the continuum of cancer care (integrating life-prolongation and palliation) . CA Cancer J Clin . 2000;50:123–132
  5. Doyle C , Crump M , Pintilie M , et al.   Does palliative chemotherapy palliate? Expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer . J Clin Oncol . 2001;19:1266–1274
  6. Koedoot CG , de Haan RJ , Stiggelbout AM , et al.   Palliative chemotherapy or best supportive care? A prospective study explaining patients’ treatment preference and choice . Br J Cancer . 2003;89:2219–2226
  7. Ranson M , Davidson N , Nicolson M , et al.   Randomized trial of paclitaxel supportive care for patients with advanced non-small cell lung cancer . J Natl Cancer Inst . 2000;92:1074–1080
  8. Daugherty C , Ratain MJ , Grochowski E , et al.   Perceptions of cancer patients and their physicians involved in phase I trials . J Clin Oncol . 1995;13:1062–1072
  9. Detmar SB , Muller MJ , Shornagel JH , et al.   Role of health-related quality of life in palliative chemotherapy treatment decisions . J Clin Oncol . 2002;20:1056–1062
  10. Osoba D , Tannock IF , Ernst DS , et al.   Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone . J Clin Oncol . 1999;17:1654–1663
  11. Tannock IF , Osoba D , Stockler MR , et al.   Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptoms in hormone-refractory prostate cancer (A Canadian randomized trial with palliative endpoints) . J Clin Oncol . 1996;14:1756–1764
  12. Gridelli C , Perrone F , Gallo C . Effects of vinorelbine on QOL and survival of elderly patients with advanced NSCLC . J Natl Cancer Institute . 1999;91:66–71
  13. Shepherd FA , Dancey J , Ramlau R , et al.   Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy . J Clin Oncol . 2000;18:2095–2103
  14. Thompson G , McClement S . Defining and determining quality end-of-life care . Int J Palliat Nurs . 2002;8:288–293
  15. Liebert MA . Medical oncology and palliative care (The intersection of end-of-life care) . J Palliat Med . 2003;6:859–861 (editorial)
  16. Definition of “to treat.” www.thefreedictionary.com/treat
  17. Hospice. A historical perspective. www.najc.org/HAA/history.html
  18. Weinreb NJ . Diagnostic tests and invasive procedures . In:  Kinzbrunner BM ,  Weinreb NJ ,  Policzer JS editor. Twenty Common Problems in End-of-Life Care . New York, NY: McGraw-Hill; 2002;p. 329–364
  19. NHPCO facts and figures. National hospice and palliative care organization. www.nhpco.org/files/public/facts_and_figures_0703.pdf
  20. Rabow MW , Dibble SL , Pantilat SZ , et al.   The comprehensive care team. A controlled trial of outpatient palliative medicine consultation . Arch Intern Med . 2004;164:83–91
  21. Ingham JM , Kachuik LE . Epidemiology of cancer at the end of life . In:  Berger AM ,  Portenoy RK ,  Weissman DE editor. Principles and Practice of Palliative Care and Supportive Oncology . (ed 2).. Philadelphia, PA: Lippincott Williams & Williams; 2002;p. 615–634
  22. Emanuel EJ , Emanuel LL . The economics of dying—The illusion of cost savings at the end of life . N Engl J Med . 1994;330:540–544
  23. Billings JA . Definitions and models of palliative care . In:  Berger AM ,  Portenoy RK ,  Weissman DE editor. Principles and Practice of Palliative Care and Supportive Oncology . (ed 2).. Philadelphia, PA: Lippincott Williams & Williams; 2002;p. 635–652
  24. Spragers LH: Creating compelling business and financial plans. www.capc.org
  25. Sachs GA . Opportunities for promoting palliative medicine in cancer research . Cancer Invest . 1995;16:503–508
  26. Casarett DJ , Karlawish JHT , Byock I . Advocacy and activism (Missing pieces in the quest to improve end-of-life care) . J Palliat Med . 2002;5:3–12
  27. McGrew DM . Why hospice needs palliative medicine and visa versa . J Palliat Med . 2003;6:337–338
  28. Casarett D , Abrahm JL . Patients with cancer referred to hospice versus a bridge program (Patient characteristics, needs for care, and survival) . J Clin Oncol . 2001;19:2057–2063
  29. Rabow MW , Petersen J , Schanche K , et al.   The comprehensive care team (A description of a controlled trial of care at the beginning of life) . J Palliat Med . 2003;6:489–499
  30. Smith T . Adding hospice and palliative care services to the cancer menu . J Palliat Med . 2003;6:641–644 (editorial)
  31. Stuart B , D’onofono CN , Beatman S , et al.   CHOICES (Promoting early access to end of life care through home-based transition management) . J Palliat Med . 2003;6:671–683
  32. Lockhart CA , Volk-Craft BE , Hamilton G , et al.   The Phoenix Care program . J Palliat Med . 2003;6:1001–1012
  33. Mission statement. www.Promotingexcellence.org/content/mission.html
  34. Jefford M , Zalcberg J . Palliative chemotherapy (A clinical oxymoron) . Lancet . 2003;362:1082; (editorial)
  35. Chang VT , Ingham J . Symptom control . Cancer Invest . 2003;21:564–578
  36. Markman M . Does palliative chemotherapy palliate? . J Support Oncol . 2003;1:65–67 (editorial)
  37. Emanuel EJ , Young-Xu Y , Levinsky NG , et al.   Chemotherapy use among Medicare beneficiaries at the end of life . Ann Intern Med . 2003;138:639–644
  38. Koedoot CG , de Haes JC , Heisterkamp SH , et al.   Palliative chemotherapy or watchful waiting? A vignettes study among oncologists . J Clin Oncol . 2002;20:3658–3664
  39. Gattellari M , Voigt KJ , Butow PN , et al.   When the treatment goal is not cure (Are cancer patients equipped to make informed decisions?) . J Clin Oncol . 2002;20:503–513
  40. Maltoni M , Amadori D . Palliative medicine and medical oncology . Ann Oncol . 2001;12:443–450
  41. Detmar SB , Aaronson NK , Wever LD , et al.   How are you feeling? Who wants to know? Patients’ and oncologists’ preferences for discussing health-related quality-of-life issues . J Clin Oncol . 2000;18:3295–3301
  42. Detmar SB , Muller MJ , Wever LD , et al.   Patient-physician communication during outpatient palliative treatment visits . JAMA . 2001;285:1351–1357
  43. Maio MD , Perrone F . Quality of life in elderly patients with cancer . Health Quality Life Outcomes . 2003;1:44–52
  44. Connors AF , Dawson NV , Desbiens NA , et al.   A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT) . JAMA . 1995;274:1591–1597
  45. Socinski MA , Morris DE , Masters GA , et al.   Chemotherapeutic management of stage IV non-small cell lung cancer . Chest . 2003;123:226S–243S
  46. Kornblith AB . Does palliative care palliate? . J Clin Oncol . 2001;19:2111–2113 (editorial)
  47. Gridelli C . Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small cell lung cancer? . Lung Cancer . 2002;38:S45–S50
  48. Bezjak A . Palliative therapy for lung cancer . Semin Surg Oncol . 2003;21:138–147
  49. Archer VR , Billingham LJ , Cullen MH . Palliative chemotherapy (No longer a contradiction in terms) . Oncologist . 1999;4:470–477
  50. Agrawal M , Danis M . End-of-life care for terminally ill participants in clinical research . J Palliat Med . 2002;5:729–737
  51. Ellison NM , Chevelen EM . Palliative chemotherapy . In:  Berger AM ,  Portenoy RK ,  Weissman DE editor. Principles and Practice of Palliative Care and Supportive Oncology . (ed 2).. Philadelphia, PA: Lippincott Williams & Williams; 2002;p. 698–709
  52. Mitchell G . Chemotherapy and radiotherapy—When to call it quits . Aust Fam Phys . 2002;31:129
  53. Henry B , Becouarn Y , Aussage P . Clinical benefits of stabilization with second line chemotherapy in patients with metastatic colorectal cancer . Crit Rev Oncol Hematol . 1999;32:145–154
  54. Von Hoff DD , Bearss D . New drugs for patients with pancreatic cancer . Cur Opinion Oncol . 2002;14:621–627
  55. El Kamar FG , Grossbard ML , Kozuch PS . Metastatic pancreatic cancer (Emerging strategies in chemotherapy and palliative care) . Oncologist . 2003;8:18–34
  56. Jacobs AD . Gemcitabine-based therapy in pancreas cancer . Cancer . 2002;95:923–927
  57. Billingham LJ , Bathers S , Burton A , et al.   Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer . Lung Cancer . 2002;37:219–225
  58. Maio MD , Perrone F , Gallo C , et al.   Supportive care in patients with advanced non-small cell lung cancer . Br J Cancer . 2003;89:1013–1021
  59. Rapp E , Pater JL , William A , et al.   Chemotherapy can prolong survival in patients with advanced NSCLC—Report of a Canadian multicenter randomized trial . J Clin Oncol . 1988;6:633–641
  60. Piper NY , Kusada L , Lance R , et al.   Adenocarcinoma of the prostate (An expensive way to die) . Prostate Cancer Prostatic Dis . 2002;5:164–166
  61. Aus G , Hugosson J , Norlen L . Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent . J Urol . 1995;154:466–469
  62. Byock I , Miles SH . Hospice benefits and phase I cancer trials . Ann Intern Med . 2003;138:335–337
  63. Casarett DJ , Karlawish JH , Henry MI , et al.   Must patients with advanced cancer choose between a phase I trial and hospice? . Cancer . 2002;95:1601–1604
  64. Meropol NJ , Weinfurt KP , Burnett CB , et al.   Perceptions of patients and physicians regarding phase I cancer clinical trials (Implications for physician-patient communication) . J Clin Oncol . 2003;21:2589–2596
  65. Kapo J , Casarett D . Palliative care in phase 1 trials (An ethical obligation or undue inducement?) . J Palliat Med . 2002;5:661–665
  66. Pentz RD , Flamm AL , Sugarman J , et al.   Study of the media’s potential influence on prospective research of participants’ understanding of and motivations for participation in a high-profile phase I trial . J Clin Oncol . 2002;20:3785–3791
  67. Bachelot T , Ray-Coquard I , Catimel G , et al.   Multivariate analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials . Ann Oncol . 2000;11:151–156
  68. Finn JW , Pienta KJ , Parzuchowski J , et al.   Palliative care project (Bridging active treatment and hospice for terminal cancer) . 2002; American Society of Clinical Oncology 38th annual meeting, Orlando, FL, May 18–21, (abstr 1452)
  69. Roychowdhury D . Phase I trials (Physician and patient perceptions) . J Clin Oncol . 2003;21:4658–4659

 Supported by Simultaneous Care Grant NIH I-R25 CA95260 (M.A.C.), and ASCO-Hartford Association Geriatric-Oncology Fellowship Training Grant (I.B.).

PII: S0093-7754(04)00571-8

doi: 10.1053/j.seminoncol.2004.11.014

Seminars in Oncology
Volume 32, Issue 2 , Pages 145-155 , April 2005

Article Tools